Pacific Biosciences Of California (PACB) Inventory (2010 - 2026)

Pacific Biosciences Of California's Inventory history runs 17 years deep, the most recent figure standing at $51.0 million for Q1 2026.

• On a quarterly basis, Inventory fell 5.53% year-over-year to $51.0 million in Q1 2026; TTM through Mar 2026 was $51.0 million, a 5.53% decrease from a year earlier, with the FY2025 full-year figure at $49.3 million, down 16.12% from the prior year.
• Inventory improved to $51.0 million in Q1 2026 per PACB's latest filing, from $49.3 million in the prior quarter.
• Across five years, Inventory topped out at $68.6 million in Q2 2024 and bottomed at $29.6 million in Q1 2022.
• The 5-year median for Inventory is $54.0 million (2025), against an average of $55.1 million.
• Across the five-year window, Inventory surged 109.13% in 2023 and retreated 21.51% in 2025, its largest moves.
• Year by year, Inventory stood at $50.4 million in 2022, then climbed by 12.49% to $56.7 million in 2023, then climbed by 3.67% to $58.8 million in 2024, then decreased by 16.12% to $49.3 million in 2025, then gained by 3.52% to $51.0 million in 2026.
• Per Business Quant, the three latest PACB Inventory figures stand at $51.0 million (Q1 2026), $49.3 million (Q4 2025), and $53.2 million (Q3 2025).